市場調査レポート：世界の原発性卵巣機能不全治療市場（～2028年）：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他

• 英文タイトル：Global Primary Ovarian Insufficiency Therapy Market Insights, Forecast to 2028

Global Primary Ovarian Insufficiency Therapy Market Insights, Forecast to 2028「世界の原発性卵巣機能不全治療市場（～2028年）：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他」（市場規模、市場予測）調査レポートです。

• レポートコード：MRC2Q12-16831
• 出版社/出版日：QYResearch / 2022年12月
• レポート形態：英文、PDF、92ページ
• 納品方法：Eメール（納期：3営業日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、原発性卵巣機能不全治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
原発性卵巣機能不全治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
原発性卵巣機能不全治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
原発性卵巣機能不全治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの原発性卵巣機能不全治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の原発性卵巣機能不全治療の売上および2028年までの予測に焦点を当てています。

原発性卵巣機能不全治療のグローバル主要企業には、Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVFなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

原発性卵巣機能不全治療市場は、タイプとアプリケーションによって区分されます。世界の原発性卵巣機能不全治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他

【アプリケーション別セグメント】
20歳以下、20～30歳、30～45歳、45歳以上

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 原発性卵巣機能不全治療製品概要
- タイプ別市場（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他）
- アプリケーション別市場（20歳以下、20～30歳、30～45歳、45歳以上）
- 調査の目的
・エグゼクティブサマリー
- 世界の原発性卵巣機能不全治療販売量予測2017-2028
- 世界の原発性卵巣機能不全治療売上予測2017-2028
- 原発性卵巣機能不全治療の地域別販売量
- 原発性卵巣機能不全治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別原発性卵巣機能不全治療販売量
- 主要メーカー別原発性卵巣機能不全治療売上
- 主要メーカー別原発性卵巣機能不全治療価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他）
- 原発性卵巣機能不全治療のタイプ別販売量
- 原発性卵巣機能不全治療のタイプ別売上
- 原発性卵巣機能不全治療のタイプ別価格
・アプリケーション別市場規模（20歳以下、20～30歳、30～45歳、45歳以上）
- 原発性卵巣機能不全治療のアプリケーション別販売量
- 原発性卵巣機能不全治療のアプリケーション別売上
- 原発性卵巣機能不全治療のアプリケーション別価格
・北米市場
- 北米の原発性卵巣機能不全治療市場規模（タイプ別、アプリケーション別）
- 主要国別の原発性卵巣機能不全治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの原発性卵巣機能不全治療市場規模（タイプ別、アプリケーション別）
- 主要国別の原発性卵巣機能不全治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の原発性卵巣機能不全治療市場規模（タイプ別、アプリケーション別）
- 主要国別の原発性卵巣機能不全治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の原発性卵巣機能不全治療市場規模（タイプ別、アプリケーション別）
- 主要国別の原発性卵巣機能不全治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの原発性卵巣機能不全治療市場規模（タイプ別、アプリケーション別）
- 主要国別の原発性卵巣機能不全治療市場規模（トルコ、サウジアラビア）
・企業情報
Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVF
・産業チェーン及び販売チャネル分析
- 原発性卵巣機能不全治療の産業チェーン分析
- 原発性卵巣機能不全治療の原材料
- 原発性卵巣機能不全治療の生産プロセス
- 原発性卵巣機能不全治療の販売及びマーケティング
- 原発性卵巣機能不全治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 原発性卵巣機能不全治療の産業動向
- 原発性卵巣機能不全治療のマーケットドライバー
- 原発性卵巣機能不全治療の課題
- 原発性卵巣機能不全治療の阻害要因
・主な調査結果

Market Analysis and Insights: Global Primary Ovarian Insufficiency Therapy Market
The global Primary Ovarian Insufficiency Therapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Hormone Replacement Therapy (HRT) accounting for % of the Primary Ovarian Insufficiency Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Less than 20 Years Old segment is altered to an % CAGR throughout this forecast period.
China Primary Ovarian Insufficiency Therapy market size is valued at US$ million in 2021, while the North America and Europe Primary Ovarian Insufficiency Therapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Primary Ovarian Insufficiency Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Ovarian Insufficiency Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Ovarian Insufficiency Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Ovarian Insufficiency Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Ovarian Insufficiency Therapy market.
Global Primary Ovarian Insufficiency Therapy Scope and Market Size
Primary Ovarian Insufficiency Therapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Primary Ovarian Insufficiency Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others
Segment by Application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older
By Company
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hormone Replacement Therapy (HRT)
1.2.3 Calcium and Vitamin D Supplements
1.2.4 In Vitro Fertilization (IVF)
1.2.5 Stem Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Less than 20 Years Old
1.3.3 20 to 30 Years Old
1.3.4 30 to 45 Years Old
1.3.5 45 Years Old and Older
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Primary Ovarian Insufficiency Therapy Market Perspective (2017-2028)
2.2 Primary Ovarian Insufficiency Therapy Growth Trends by Region
2.2.1 Primary Ovarian Insufficiency Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Primary Ovarian Insufficiency Therapy Historic Market Size by Region (2017-2022)
2.2.3 Primary Ovarian Insufficiency Therapy Forecasted Market Size by Region (2023-2028)
2.3 Primary Ovarian Insufficiency Therapy Market Dynamics
2.3.1 Primary Ovarian Insufficiency Therapy Industry Trends
2.3.2 Primary Ovarian Insufficiency Therapy Market Drivers
2.3.3 Primary Ovarian Insufficiency Therapy Market Challenges
2.3.4 Primary Ovarian Insufficiency Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue
3.1.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue (2017-2022)
3.1.2 Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Primary Ovarian Insufficiency Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Ovarian Insufficiency Therapy Revenue
3.4 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio
3.4.1 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Ovarian Insufficiency Therapy Revenue in 2021
3.5 Primary Ovarian Insufficiency Therapy Key Players Head office and Area Served
3.6 Key Players Primary Ovarian Insufficiency Therapy Product Solution and Service
3.7 Date of Enter into Primary Ovarian Insufficiency Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Ovarian Insufficiency Therapy Breakdown Data by Type
4.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Type (2017-2022)
4.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Type (2023-2028)
5 Primary Ovarian Insufficiency Therapy Breakdown Data by Application
5.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Application (2017-2022)
5.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Primary Ovarian Insufficiency Therapy Market Size (2017-2028)
6.2 North America Primary Ovarian Insufficiency Therapy Market Size by Type
6.2.1 North America Primary Ovarian Insufficiency Therapy Market Size by Type (2017-2022)
6.2.2 North America Primary Ovarian Insufficiency Therapy Market Size by Type (2023-2028)
6.2.3 North America Primary Ovarian Insufficiency Therapy Market Share by Type (2017-2028)
6.3 North America Primary Ovarian Insufficiency Therapy Market Size by Application
6.3.1 North America Primary Ovarian Insufficiency Therapy Market Size by Application (2017-2022)
6.3.2 North America Primary Ovarian Insufficiency Therapy Market Size by Application (2023-2028)
6.3.3 North America Primary Ovarian Insufficiency Therapy Market Share by Application (2017-2028)
6.4 North America Primary Ovarian Insufficiency Therapy Market Size by Country
6.4.1 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2017-2022)
6.4.2 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Primary Ovarian Insufficiency Therapy Market Size (2017-2028)
7.2 Europe Primary Ovarian Insufficiency Therapy Market Size by Type
7.2.1 Europe Primary Ovarian Insufficiency Therapy Market Size by Type (2017-2022)
7.2.2 Europe Primary Ovarian Insufficiency Therapy Market Size by Type (2023-2028)
7.2.3 Europe Primary Ovarian Insufficiency Therapy Market Share by Type (2017-2028)
7.3 Europe Primary Ovarian Insufficiency Therapy Market Size by Application
7.3.1 Europe Primary Ovarian Insufficiency Therapy Market Size by Application (2017-2022)
7.3.2 Europe Primary Ovarian Insufficiency Therapy Market Size by Application (2023-2028)
7.3.3 Europe Primary Ovarian Insufficiency Therapy Market Share by Application (2017-2028)
7.4 Europe Primary Ovarian Insufficiency Therapy Market Size by Country
7.4.1 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2017-2022)
7.4.2 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size (2017-2028)
8.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Type
8.2.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Share by Type (2017-2028)
8.3 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Application
8.3.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region
8.4.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Primary Ovarian Insufficiency Therapy Market Size (2017-2028)
9.2 Latin America Primary Ovarian Insufficiency Therapy Market Size by Type
9.2.1 Latin America Primary Ovarian Insufficiency Therapy Market Size by Type (2017-2022)
9.2.2 Latin America Primary Ovarian Insufficiency Therapy Market Size by Type (2023-2028)
9.2.3 Latin America Primary Ovarian Insufficiency Therapy Market Share by Type (2017-2028)
9.3 Latin America Primary Ovarian Insufficiency Therapy Market Size by Application
9.3.1 Latin America Primary Ovarian Insufficiency Therapy Market Size by Application (2017-2022)
9.3.2 Latin America Primary Ovarian Insufficiency Therapy Market Size by Application (2023-2028)
9.3.3 Latin America Primary Ovarian Insufficiency Therapy Market Share by Application (2017-2028)
9.4 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country
9.4.1 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2017-2022)
9.4.2 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size (2017-2028)
10.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Type
10.2.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Share by Type (2017-2028)
10.3 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Application
10.3.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country
10.4.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Primary Ovarian Insufficiency Therapy Introduction
11.1.4 Pfizer Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.1.5 Pfizer Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Primary Ovarian Insufficiency Therapy Introduction
11.2.4 Bayer Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.2.5 Bayer Recent Developments
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Primary Ovarian Insufficiency Therapy Introduction
11.3.4 Novartis Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.3.5 Novartis Recent Developments
11.4 Bioscience Institute
11.4.1 Bioscience Institute Company Details
11.4.2 Bioscience Institute Business Overview
11.4.3 Bioscience Institute Primary Ovarian Insufficiency Therapy Introduction
11.4.4 Bioscience Institute Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.4.5 Bioscience Institute Recent Developments
11.5 Johns Hopkins Medicine
11.5.1 Johns Hopkins Medicine Company Details
11.5.2 Johns Hopkins Medicine Business Overview
11.5.3 Johns Hopkins Medicine Primary Ovarian Insufficiency Therapy Introduction
11.5.4 Johns Hopkins Medicine Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.5.5 Johns Hopkins Medicine Recent Developments
11.6 Mayo Clinic
11.6.1 Mayo Clinic Company Details
11.6.2 Mayo Clinic Business Overview
11.6.3 Mayo Clinic Primary Ovarian Insufficiency Therapy Introduction
11.6.4 Mayo Clinic Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.6.5 Mayo Clinic Recent Developments
11.7 Baptist Health
11.7.1 Baptist Health Company Details
11.7.2 Baptist Health Business Overview
11.7.3 Baptist Health Primary Ovarian Insufficiency Therapy Introduction
11.7.4 Baptist Health Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.7.5 Baptist Health Recent Developments
11.8 Indira IVF
11.8.1 Indira IVF Company Details
11.8.2 Indira IVF Business Overview
11.8.3 Indira IVF Primary Ovarian Insufficiency Therapy Introduction
11.8.4 Indira IVF Revenue in Primary Ovarian Insufficiency Therapy Business (2017-2022)
11.8.5 Indira IVF Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer